Search tips
Search criteria 


Logo of tobcontTobacco ControlVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
Tob Control. 2005 June; 14(3): 193–200.
PMCID: PMC1343526

Understanding Philip Morris's pursuit of US government regulation of tobacco


Objective: To investigate Philip Morris's support of US Food and Drug Administration (FDA) regulation of tobacco products and analyse its relationship to the company's image enhancement strategies.

Data sources: Internal Philip Morris documents released as part of the Master Settlement Agreement.

Methods: Searches of the Legacy Tobacco Documents Library ( beginning with such terms as "FDA" and "regulatory strategy" and expanding to include relevant new terms.

Results: Philip Morris's support for government regulation of tobacco is part of a broader effort to address its negative public image, which has a damaging impact on the company's stock price, political influence, and employee morale. Through regulation, the company seeks to enhance its legitimacy, redefine itself as socially responsible, and alter the litigation environment. Whereas health advocates frame tobacco use as a public health policy issue, Philip Morris's regulatory efforts focus on framing tobacco use as an individual choice by informed adults to use a risky product. This framing allows Philip Morris to portray itself as a reasonable and responsible manufacturer and marketer of risky products.

Conclusions: Philip Morris's ability to improve its image through support of FDA regulation may undermine tobacco control efforts aimed at delegitimising the tobacco industry. It may also create the impression that Philip Morris's products are being made safer and ultimately protect the company from litigation. While strong regulation of tobacco products and promotion remain critical public health goals, previous experiences with tobacco regulation show that caution may be warranted.

Full Text

The Full Text of this article is available as a PDF (216K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Malone RE, Balbach ED. Tobacco industry documents: treasure trove or quagmire? Tob Control. 2000 Sep;9(3):334–338. [PMC free article] [PubMed]
  • Balbach ED, Gasior RJ, Barbeau EM. Tobacco industry documents: comparing the Minnesota Depository and internet access. Tob Control. 2002 Mar;11(1):68–72. [PMC free article] [PubMed]
  • KLISIECKI A, WIKTOR Z, PYTASZ M, DEC L. [Alkalization, ammonia and urea in urine in kidney diseases]. Pol Tyg Lek. 1961 Dec 25;16:2001–2004. [PubMed]
  • Smith EA, Malone RE. Thinking the "unthinkable": why Philip Morris considered quitting. Tob Control. 2003 Jun;12(2):208–213. [PMC free article] [PubMed]
  • Smith Elizabeth A, Malone Ruth E. Altria means tobacco: Philip Morris's identity crisis. Am J Public Health. 2003 Apr;93(4):553–556. [PubMed]
  • Camilleri-Broët S, Hardy-Bessard AC, Le Tourneau A, Paraiso D, Levrel O, Leduc B, Bain S, Orfeuvre H, Audouin J, Pujade-Lauraine E, et al. HER-2 overexpression is an independent marker of poor prognosis of advanced primary ovarian carcinoma: a multicenter study of the GINECO group. Ann Oncol. 2004 Jan;15(1):104–112. [PubMed]
  • Farrelly Matthew C, Healton Cheryl G, Davis Kevin C, Messeri Peter, Hersey James C, Haviland M Lyndon. Getting to the truth: evaluating national tobacco countermarketing campaigns. Am J Public Health. 2002 Jun;92(6):901–907. [PubMed]
  • Niederdeppe Jeff, Farrelly Matthew C, Haviland M Lyndon. Confirming "truth": more evidence of a successful tobacco countermarketing campaign in Florida. Am J Public Health. 2004 Feb;94(2):255–257. [PubMed]
  • Doll R, Peto R, Wheatley K, Gray R, Sutherland I. Mortality in relation to smoking: 40 years' observations on male British doctors. BMJ. 1994 Oct 8;309(6959):901–911. [PMC free article] [PubMed]

Articles from Tobacco Control are provided here courtesy of BMJ Publishing Group